格隆汇11月29日丨精优药业(00858.HK)公告,于2024年中期期间,集团录得收益约30,800,000港元(主要来自于中国经营的制造分类),较上年同期呈报的收益约30,100,000港元增加约700,000港元。于2024年中期期间,集团录得除税后溢利约101,500,000港元,而2023年中期期间则录得除税后亏损约236,900,000港元,转亏为盈主要由于按公平值计入损益的金融资产(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.